Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by pelabooston Dec 15, 2023 2:20pm
237 Views
Post# 35787194

Multiple Myeloma In General and NCT03605719 Specifically

Multiple Myeloma In General and NCT03605719 SpecificallyA poster elsewhere mentioned MM results, and I cannot find them.

I was prompted to look up the above noted MM trial. It added the CPI Opdivo - BMS. It is worth noting that this trial added the CPI to a combo that was already said to have been very promising. It is also worth noting that the Actual Completion Date was October 2022, as compared to the Anticipated date of May 2024. In my limited experience those dates are usually reveresed; that is to say actual date is after the anticipated date. This was a Phase 1 trial.

Another note of interest; it is possible but highly unlikely to receive Accelerated Approval off a Phase 1 trial. I am in no way suggesting that that factoid applies to the above.

Three Questions.
1. What MM trial was the other poster referring to?
2. If not the above trial, where are the results for it?
and most importantly
3. Is there an effort at Head Office to package and present all the goods ONC/Y has to offer?

<< Previous
Bullboard Posts
Next >>